AHA 2023 CardioNerds Conference Scholars Late-Breaking Video Collection
Published: 16 November 2023
-
Views:
2166
-
Likes:
7
-
Views:
2166
-
Likes:
7
-
Up Next -
11m 47sPart 1 | Session 2 SELECT: Effects of Semaglutide on Heart Disease & Stroke in Obese Patients -
16m 5sPart 1 | Session 3 MINT: Myocardial Ischaemia & Transfusion -
11m 41sPart 1 | Session 4 KARDIA-1: ALN-AGT01 in Patients With Mild-to Moderate Hypertension -
8m 35sPart 1 | Session 5 CordiO App: Speech Analysis to Detect Worsening HF in ADHF Patients -
14m 32sPart 1 | Session 6 AHA23: Presidential Advisory on Cardiovascular-Kidney-Metabolic Health -
10m 36sPart 1 | Session 7 AZALEA-TIMI 71: Abelcibab Vs Rivaroxaban in Patients with AF -
9m 14sPart 1 | Session 8 An Extended Duration Short-Interfering RNA Targeting Lp(a) -
11m 15sPart 1 | Session 9 ARTESiA: Stroke Risk Reduction in Sub-Clinical AF: Apixaban vs Aspirin -
15m 26sPart 1 | Session 10 ARIES HM3: Avoidance of Aspirin with LVAD Devices
Overview
In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family.
These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.
More from this programme
Part 1
Radcliffe & Cardionerds @AHA23
About the episode
AHA 2023 — Investigators of ORBITA-2 trial, Dr Rasha Al-Lamee and Dr Christopher Rajkumar (Imperial College London, UK) talked with CardioNerds Ambassador, Dr Nazli Okumus about the randomised, placebo-controlled trial (NCT03742050) that compared the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy at 12 weeks.
The ORBITA-2 trial enrolled 439 patients eligible for percutaneous coronary intervention (PCI), who met specific inclusion criteria. These criteria included the presence of angina or angina-equivalent symptoms, the presence of anatomical evidence showing severe coronary stenosis in at least one vessel as determined through invasive diagnostic angiography or computerized tomography coronary angiography (CTCA), as well as the manifestation of evidence indicating myocardial ischemia. The primary outcome is an angina symptom score measured daily.
Findings suggest that in stable angina, PCI without anti-anginal therapy improved angina symptom score, reduced angina frequency, increased exercise capacity and improved quality of life. The effect of PCI was immediate and sustained over 12 weeks, however, this effect size was smaller than in comparable unblinded trials.
Recorded on-site at AHA 2023, Philadelphia.
Supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.
Faculty Biographies
Rasha Al-Lamee
Interventional Cardiology Consultant
Dr Rasha Al-Lamee is an interventional cardiology consultant at Imperial College Healthcare NHS Trust, London, UK.
Dr Al-Lamee studied at the University of Oxford and University College London. She completed her training in clinical cardiology on the north-west London cardiology rotation in 2013, and completed her PhD at Imperial College London in 2018.
Dr Al-Lamee’s research interests are complex coronary intervention, coronary physiology and invasive intravascular assessment. She designed, conducted and led the ORBITA trial and is lead author of the primary publication in The Lancet. Dr Al-Lamee has more than 50 peer-reviewed publications and has presented at international cardiology conferences worldwide.
Nazli Okumus
Dr. Nazli Okumus is currently in her third year as a Cardiology Fellow at Allegheny Health Network (AHN) in Pittsburgh, PA, where she is dedicated to advancing her training in interventional cardiology. She successfully completed her residency at Case Western MetroHealth in Cleveland, OH. Her commitments extend to serving as a member of the SCAI Political Action Committee, contributing to the ACC FIT Editorial Fellowship program Advocacy section, and acting as the CardioNerds Ambassador, representing her fellowship program while participating in the CardioNerds IC and CCC committees. In addition, she is actively engaged in digital education and mentorship, with a particular emphasis on empowering women in medicine. Her research and clinical interests encompass cardiogenic shock, valvular heart disease, and complex coronary interventions. Dr. Okumus is fervently committed to patient advocacy and addressing health disparities.
Comments